跳至主要内容
临床试验/NCT03535506
NCT03535506终止2 期

Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

Georgetown University2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2018年10月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
17
试验地点
2
主要终点
Feasibility: Recruitment Rates

研究概览

简要总结

This is a feasibility study which will evaluate the effects of pre-operative treatment of DCIS of the breast with palbociclib. Patients with biopsy-proven DCIS are eligible for the study.

There will be 2 independent and unrelated study groups of 12 patients each, for a total of 24 patients:

  1. Group A, of male or female patients treated with palbociclib single agent (n=12);
  2. Group B, untreated, of male or female patients who consented translational studies in blood, as well as diagnostic and definitive surgical specimen, but not the pre-operative treatment with palbociclib (n=12).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Group A

Experimental

Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.

干预措施: Palbociclib (Drug)

结局指标

主要结局

Feasibility: Recruitment Rates

时间窗: 5 years

The approach will be considered feasible if more than 50% of the enrolled patients are treated andcomplete the study.

次要结局

  • Pathologic Changes(2 months)
  • Pathology Changes on Immunohistochemistry (IHC)(2 months)
  • Toxcity Based on CTCAE(3 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Preoperative Palbociclib in Patients With DCIS of... | 临床试验